Immunotherapy of leukemia and lymphoma

S. Murphy, Evan M Hersh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Clinical trials in leukemia and lymphoma have provided suggestive evidence that immunotherapy contributes to the overall management of these neoplasms. Not all disease categories nor every patient within a category has benefited from the specific immunotherapy they have received. In fact, there is certain evidence that overstimulation as well as inadequate stimulation may be harmful. Advances in knowledge of the biologic importance of general and specific immunocompetence should lead to a more rational use of immunotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)181-203
Number of pages23
JournalSeminars in Hematology
Volume15
Issue number2
StatePublished - 1978
Externally publishedYes

Fingerprint

Immunotherapy
Lymphoma
Leukemia
Immunocompetence
Clinical Trials
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Immunotherapy of leukemia and lymphoma. / Murphy, S.; Hersh, Evan M.

In: Seminars in Hematology, Vol. 15, No. 2, 1978, p. 181-203.

Research output: Contribution to journalArticle

Murphy, S & Hersh, EM 1978, 'Immunotherapy of leukemia and lymphoma', Seminars in Hematology, vol. 15, no. 2, pp. 181-203.
Murphy, S. ; Hersh, Evan M. / Immunotherapy of leukemia and lymphoma. In: Seminars in Hematology. 1978 ; Vol. 15, No. 2. pp. 181-203.
@article{271d19510284433d8e24d21fde5a736b,
title = "Immunotherapy of leukemia and lymphoma",
abstract = "Clinical trials in leukemia and lymphoma have provided suggestive evidence that immunotherapy contributes to the overall management of these neoplasms. Not all disease categories nor every patient within a category has benefited from the specific immunotherapy they have received. In fact, there is certain evidence that overstimulation as well as inadequate stimulation may be harmful. Advances in knowledge of the biologic importance of general and specific immunocompetence should lead to a more rational use of immunotherapeutic agents.",
author = "S. Murphy and Hersh, {Evan M}",
year = "1978",
language = "English (US)",
volume = "15",
pages = "181--203",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Immunotherapy of leukemia and lymphoma

AU - Murphy, S.

AU - Hersh, Evan M

PY - 1978

Y1 - 1978

N2 - Clinical trials in leukemia and lymphoma have provided suggestive evidence that immunotherapy contributes to the overall management of these neoplasms. Not all disease categories nor every patient within a category has benefited from the specific immunotherapy they have received. In fact, there is certain evidence that overstimulation as well as inadequate stimulation may be harmful. Advances in knowledge of the biologic importance of general and specific immunocompetence should lead to a more rational use of immunotherapeutic agents.

AB - Clinical trials in leukemia and lymphoma have provided suggestive evidence that immunotherapy contributes to the overall management of these neoplasms. Not all disease categories nor every patient within a category has benefited from the specific immunotherapy they have received. In fact, there is certain evidence that overstimulation as well as inadequate stimulation may be harmful. Advances in knowledge of the biologic importance of general and specific immunocompetence should lead to a more rational use of immunotherapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0018179129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018179129&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 181

EP - 203

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2

ER -